Indivior Pharmaceuticals, Inc.

INDV

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Driehaus Capital Rock Springs Capital Deerfield Management

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 2,000,339Value: $71.8M

# Signal Note: Driehaus Initiates $71.8M INDV Position Driehaus's initiation of a 2M+ share stake in Indivior signals conviction in the company's opioid addiction franchise, primarily buprenorphine products (Suboxone film, generics competition notwithstanding) and pipeline candidates like CODS (sublocade competitor). The entry size ($71.8M, ~1.4% of Driehaus biotech allocation) suggests medium-conviction thesis rather than core holding; timing may reflect valuation recovery post-litigation settlements or upcoming catalyst visibility (pipeline readouts, market share stabilization in medication-assisted treatment).

Rock Springs CapitalNEW

More INDV Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds ALNY3 funds ATEC3 funds BSX3 funds BBIO3 funds XENE3 funds INSP3 funds RVMD

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Rock Springs Capital Initiates INDV Position Rock Springs' $3.8M entry into Indivior suggests conviction in the company's opioid addiction treatment portfolio, likely centered on buprenorphine formulations (Suboxone franchise) and newer candidates like VIVITROL. The timing may reflect confidence in recent or upcoming clinical data, label expansion opportunities, or valuation reset following prior legal settlements. Given Rock Springs' healthcare specialization and concentrated approach, this signals potential catalyst visibility over near-to-medium term.